Barclays PLC Has $4.35 Million Stock Holdings in Ligand

Dec 22, 2024 · Barclays PLC grew its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 20.0% during the 3rd quarter, according to its most recent …

0%
OFF

Barclays PLC Has $4.35 Million Stock Holdings In Ligand

2 weeks from now

Dec 22, 2024 · Barclays PLC grew its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 20.0% during the 3rd quarter, according to its most recent …

marketbeat.com

0%
OFF

Ligand Pharmaceuticals (LGND) News Today - MarketBeat

2 weeks from now

2 days ago · Barclays PLC increased its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 20.0% during the 3rd quarter, according to the company in …

marketbeat.com

$376798956000
OFF

BARCLAYS PLC Top 13F Holdings - WhaleWisdom.com

2 weeks from now

Sep 30, 2024 · Barclays PLC is based out of London. Their last reported 13F filing for Q3 2024 included $376,798,956,000 in managed 13F securities and a top 10 holdings concentration of …

whalewisdom.com

4%
OFF

Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares Purchased By …

2 weeks from now

1 day ago · Barclays PLC raised its holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 357.4% during the third quarter, according to its most recent filing with the …

marketbeat.com

$110.00
OFF

Barclays Remains A Buy On Ligand Pharma (LGND) - Markets Insider

2 weeks from now

Jan 29, 2024 · In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Ligand Pharma ( LGND – Research Report ), with a price target of $110.00. The company’s …

businessinsider.com

1%
OFF

Barclays PLC Has $4.37 Million Stock Holdings In Jazz …

2 weeks from now

Dec 22, 2024 · Barclays PLC increased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 19.1% during the 3rd quarter, according to the company in …

etfdailynews.com

$264000
OFF

Barclays PLC Has $264,000 Stock Holdings In Rapport Therapeutics ...

2 weeks from now

The fund owned 12,863 shares of the company’s stock after purchasing an additional 3,463 shares during the period. Barclays PLC’s holdings in Rapport Therapeutics were worth …

etfdailynews.com

13%
OFF

Barclays PLC Has $255,000 Stock Holdings In Atossa Therapeutics, …

2 weeks from now

Jan 6, 2025 · The fund owned 167,718 shares of the company’s stock after purchasing an additional 123,683 shares during the quarter. Barclays PLC owned about 0.13% of Atossa …

defenseworld.net

$79000
OFF

Barclays PLC Has $79,000 Stock Holdings In Karyopharm …

2 weeks from now

5 days ago · The stock has a market cap of $90.35 million, a P/E ratio of -0.63 and a beta of 0.07. Karyopharm Therapeutics Inc. has a 52-week low of $0.58 and a 52-week high of $1.95.

defenseworld.net

10%
OFF

Barclays PLC Increases Stock Holdings In Preformed Line Products ...

2 weeks from now

Jan 2, 2025 · The fund owned 4,989 shares of the technology company’s stock after buying an additional 2,871 shares during the quarter. Barclays PLC owned about 0.10% of Preformed …

defenseworld.net

$4.37
OFF

Barclays PLC Has $4.37 Million Stock Position In Jazz ... - MarketBeat

2 weeks from now

Dec 22, 2024 · The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of …

marketbeat.com

8%
OFF

Barclays PLC Has $4.98 Million Stock Holdings In ACV Auctions Inc ...

2 weeks from now

Dec 21, 2024 · Barclays PLC increased its position in shares of ACV Auctions Inc. (NASDAQ:ACVA – Free Report) by 16.8% in the third quarter, according to its most recent …

etfdailynews.com

0%
OFF

Barclays PLC Has $4.35 Million Stock Holdings In Ligand …

2 weeks from now

Dec 22, 2024 · Barclays PLC increased its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 20.0% during the 3rd quarter, according to …

etfdailynews.com

5%
OFF

Barclays PLC Has $308,000 Stock Position In EGain Co.

2 weeks from now

Jan 5, 2025 · Barclays PLC lifted its holdings in shares of eGain Co. (NASDAQ:EGAN – Free Report) by 48.5% during the third quarter, according to the company in its most recent Form …

tickerreport.com

6%
OFF

Barclays PLC Has $1.99 Million Stock Holdings In Cohu, Inc.

2 weeks from now

Dec 27, 2024 · Barclays PLC increased its holdings in shares of Cohu, Inc. (NASDAQ:COHU – Free Report) by 331.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 77,600 …

tickerreport.com

$1.31
OFF

Barclays PLC Has $1.31 Million Stock Holdings In Bristow Group Inc ...

2 weeks from now

Dec 29, 2024 · The institutional investor owned 37,691 shares of the company’s stock after buying an additional 27,953 shares during the period. Barclays PLC’s holdings in Bristow …

etfdailynews.com

9%
OFF

Heidrick & Struggles International, Inc. (NASDAQ:HSII) Stake …

2 weeks from now

2 days ago · Barclays PLC boosted its stake in Heidrick & Struggles International, Inc. (NASDAQ:HSII - Free Report) by 280.9% during the 3rd quarter, according to its most recent …

marketbeat.com

3%
OFF

Barclays PLC Has $3.93 Million Holdings In Repligen Co.

2 weeks from now

Dec 23, 2024 · Barclays PLC lessened its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 87.3% in the 3rd quarter, Holdings Channel reports. The fund owned 26,395 shares …

americanbankingnews.com

2%
OFF

Barclays PLC Has $1.15 Million Stock Holdings In Cipher Mining Inc ...

2 weeks from now

Dec 30, 2024 · Barclays PLC raised its position in Cipher Mining Inc. (NASDAQ:CIFR - Free Report) by 377.2% in the 3rd quarter, according to the company in its most recent filing with …

marketbeat.com

FAQs about Barclays PLC Has $4.35 Million Stock Holdings in Ligand Coupon?

Does Barclays PLC own Ligand Pharmaceuticals?

Barclays PLC owned 0.23% of Ligand Pharmaceuticals worth $4,349,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. ...

Does Barclays PLC own rapport Therapeutics?

The fund owned 12,863 shares of the company’s stock after purchasing an additional 3,463 shares during the period. Barclays PLC’s holdings in Rapport Therapeutics were worth $264,000 at the end of the most recent quarter. A number of other hedge funds have also modified their holdings of RAPP. ...

Does Barclays PLC own ACV Auctions Inc (ACVA)?

Barclays PLC increased its position in shares of ACV Auctions Inc. (NASDAQ:ACVA – Free Report) by 16.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 244,999 shares of the company’s stock after purchasing an additional 35,155 shares during the quarter. ...

Who owns Ligand Pharmaceuticals?

Headlands Technologies LLC now owns 758 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 135 shares during the period. Finally, Benjamin F. Edwards & Company Inc. bought a new position in Ligand Pharmaceuticals in the second quarter valued at about $67,000. ...

Is Ligand Pharmaceuticals a good stock to buy?

Benchmark upped their target price on shares of Ligand Pharmaceuticals from $110.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating on shares of Ligand Pharmaceuticals in a research note on Wednesday, December 11th. ...

Does Barclays PLC own Bristow Group?

Barclays PLC’s holdings in Bristow Group were worth $1,308,000 as of its most recent SEC filing. Other large investors have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its position in Bristow Group by 7.1% in the 2nd quarter. ...